- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07441694
Studie av INCA036978 hos deltagare med myeloproliferativa neoplasi
En fas 1, öppen, multicenterstudie av INCA036978 hos deltagare med myeloproliferativa neoplasi
This study will be conducted to determine the safety, tolerability, dose-limiting toxicity (DLT)s, and maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE)s of INCA036978 administered as monotherapy and in combination with a standard disease-directed therapy.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Incyte Corporation Call Center (US)
- Telefonnummer: 1.855.463.3463
- E-post: medinfo@incyte.com
Studera Kontakt Backup
- Namn: Incyte Corporation Call Center (ex-US)
- Telefonnummer: +800 00027423
- E-post: eumedinfo@incyte.com
Studieorter
-
-
New South Wales
-
Concord, New South Wales, Australien, 02139
- Rekrytering
- Concord General Repatriation Hospital
-
St Leonards, New South Wales, Australien, 02065
- Rekrytering
- Royal North Shore Hospital
-
-
Queensland
-
Auchenflower, Queensland, Australien, 04066
- Rekrytering
- Icon Cancer Centre
-
-
Victoria
-
East Melbourne, Victoria, Australien, 03002
- Rekrytering
- Epworth Health Care
-
-
Western Australia
-
Nedlands, Western Australia, Australien, 06009
- Rekrytering
- Linear Clinical Research
-
-
-
-
-
Liège, Belgien, 04000
- Har inte rekryterat ännu
- Centre Hospitalier Universitaire (Chu) de Liege
-
Roeselare, Belgien, 08800
- Har inte rekryterat ännu
- AZ DELTA
-
-
-
-
-
Bordeaux, Frankrike, 33076
- Rekrytering
- Francois-Xavier
-
Paris, Frankrike, 75010
- Rekrytering
- Hospital Saint Louis
-
Villejuif, Frankrike, 94805
- Rekrytering
- Institut Gustave Roussy
-
-
-
-
Alabama
-
Birmingham, Alabama, Förenta staterna, 35233
- Har inte rekryterat ännu
- University of Alabama At Birmingham
-
-
California
-
Irvine, California, Förenta staterna, 92618
- Rekrytering
- City of Hope-Lennar Foundation Cancer Center
-
Los Angeles, California, Förenta staterna, 90095
- Har inte rekryterat ännu
- UCLA Medical Hematology & Oncology
-
Los Angeles, California, Förenta staterna, 90033
- Har inte rekryterat ännu
- Usc Norris Comprehensive Cancer Center
-
-
Connecticut
-
New Haven, Connecticut, Förenta staterna, 06510
- Har inte rekryterat ännu
- Yale Cancer Center
-
-
Florida
-
Miami, Florida, Förenta staterna, 33136
- Har inte rekryterat ännu
- University of Miami
-
Tampa, Florida, Förenta staterna, 33612
- Har inte rekryterat ännu
- Moffitt Cancer Center
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30322
- Rekrytering
- Winship Cancer Institute of Emory University
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21287
- Har inte rekryterat ännu
- John Hopkins Hospital
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02114
- Rekrytering
- Massachusetts General Hospital
-
-
Missouri
-
St Louis, Missouri, Förenta staterna, 63108
- Har inte rekryterat ännu
- Washington University School of Medicine
-
-
New York
-
New York, New York, Förenta staterna, 10065
- Har inte rekryterat ännu
- Weill Cornell Medicine
-
New York, New York, Förenta staterna, 10029
- Har inte rekryterat ännu
- Mount Sinai School of Medicine
-
New York, New York, Förenta staterna, 10021
- Har inte rekryterat ännu
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Chapel Hill, North Carolina, Förenta staterna, 27514
- Rekrytering
- University of North Carolina At Chapel Hill
-
Charlotte, North Carolina, Förenta staterna, 28204
- Har inte rekryterat ännu
- Levine Cancer Institute
-
Durham, North Carolina, Förenta staterna, 27705
- Har inte rekryterat ännu
- Duke University Medical Center, Department of Hematologic Malignancies and Cellular Therapy
-
-
Ohio
-
Cleveland, Ohio, Förenta staterna, 44195
- Har inte rekryterat ännu
- Cleveland Clinic
-
Columbus, Ohio, Förenta staterna, 43210
- Rekrytering
- Ohio State University
-
-
Tennessee
-
Nashville, Tennessee, Förenta staterna, 37203
- Rekrytering
- Tristar Bmt/Tcto
-
-
Texas
-
Houston, Texas, Förenta staterna, 77030
- Har inte rekryterat ännu
- University of Texas M. D. Anderson Cancer Center
-
-
Utah
-
Salt Lake City, Utah, Förenta staterna, 84112
- Har inte rekryterat ännu
- Huntsman Cancer Institute
-
-
Wisconsin
-
Milwaukee, Wisconsin, Förenta staterna, 53226
- Har inte rekryterat ännu
- Medical College of Wisconsin
-
-
-
-
-
Bologna, Italien, 40138
- Har inte rekryterat ännu
- Aou Policlinico S. Orsola-Malpighi
-
Milan, Italien, 20122
- Har inte rekryterat ännu
- Fondazione Irccs Ca' Granda - Ospedale Maggiore Policlinico
-
Roma, Italien, 00168
- Har inte rekryterat ännu
- A. Gemelli University Hospital, Catholic University of the Sacred Heart
-
Udine, Italien, 33100
- Har inte rekryterat ännu
- Azienda Sanitaria Universitaria Friuli Centrale Asu Fc
-
-
-
-
-
Kashiwa Chiba, Japan, 277-0882
- Har inte rekryterat ännu
- National Cancer Center Hospital East
-
Toon, Ehime, Japan, 791-0204
- Har inte rekryterat ännu
- Ehime University Hospital
-
-
-
-
Ontario
-
Toronto, Ontario, Kanada, M5G 2M9
- Rekrytering
- Princess Margaret Cancer Centre
-
-
Quebec
-
Montreal, Quebec, Kanada, H3T 1E2
- Har inte rekryterat ännu
- McGill University Jewish General Hospital
-
-
-
-
-
Badalona, Spanien, 08916
- Har inte rekryterat ännu
- Hospital Universitari Germans Trias I Pujol
-
Las Palmas de Gran Canaria, Spanien, 35010
- Har inte rekryterat ännu
- Hospital Universitario de Gran Canaria Dr. Negrin
-
Madrid, Spanien, 28041
- Har inte rekryterat ännu
- Hospital Universitario 12 de Octubre
-
-
-
-
-
London, Storbritannien, SE1 9RT
- Har inte rekryterat ännu
- Guy'S Hospital - Guy'S & St Thomas' Nhs Foundation Trust
-
Nottingham, Storbritannien, NG5 1PB
- Har inte rekryterat ännu
- Nottingham University Hospitals
-
Oxford, Storbritannien, OX3 7LE
- Rekrytering
- University of Oxford
-
-
-
-
-
Jongno-gu, Seoul, Sydkorea, 03080
- Har inte rekryterat ännu
- Seoul National University Hospital
-
Seocho-gu, Seoul, Sydkorea, 06591
- Har inte rekryterat ännu
- The Catholic University of Korea Seoul St. Mary'S Hospital
-
-
-
-
-
Aachen, Tyskland, D-52074
- Rekrytering
- University Medical Center Rwth Aachen
-
Berlin, Tyskland, 10117
- Rekrytering
- Charite Universitaetsmedizin Berlin - Campus Charite Mitte
-
Freiburg im Breisgau, Tyskland, 79106
- Rekrytering
- Universitatklinikum Freiburg
-
Halle, Tyskland, 06120
- Rekrytering
- Universitatsklinikum Halle (Saale)
-
Mainz, Tyskland, 55131
- Har inte rekryterat ännu
- Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Life expectancy > 6 months.
- Willingness to undergo a pretreatment and limited on-study BM biopsies and aspirates (as appropriate to disease).
- Participants with MF, PV and ET as defined in the protocol.
Exclusion Criteria:
- Presence of any hematological malignancy other than MF, PV, or ET.
- Malignancy within the last 3 years prior to enrollment.
- Acute or chronic HBV, Active HCV or known HIV or tuberculosis infection.
- Clinically significant or uncontrolled cardiac disease.
- Has undergone any prior allogeneic stem-cell transplantation or such transplantation is planned in the next 6 months.
- Laboratory values outside the Protocol-defined ranges.
- Prior history of major bleeding or thrombosis within the last 3 months prior to study enrollment.
- Presence of chronic or current active infectious disease requiring systemic treatment.
- Treatment with an MPN-directed therapy (approved or investigational) within the per protocol threshold before the administration of study drug.
- Prior radiation therapy within 28 days before the first dose of study treatment.
Other protocol-defined Inclusion/Exclusion Criteria may apply.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Sekventiell tilldelning
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Part 1a: Dose Escalation
INCA036978 will be administered at a protocol defined starting regimen as monotherapy to identify the MTD and/or RDE(s). |
INCA036978 will be administered at protocol defined dose. |
|
Experimentell: Part 1b: Dose Escalation
INCA036978 will be administered at a protocol defined starting regimen in combination with a standard disease-directed therapy to identify the MTD and/or RDE(s). |
INCA036978 will be administered at protocol defined dose. A standard disease-directed therapy will be administered according to Prescribing Information/SmPC. |
|
Experimentell: Part 2a: Dose Expansion
INCA036978 will be administered as monotherapy at the RDE(s) identified during Part 1 |
INCA036978 will be administered at protocol defined dose. |
|
Experimentell: Part 2b: Dose Expansion
INCA036978 will be administered in combination with a standard disease-directed therapy at the RDE(s) identified during Part 1. |
INCA036978 will be administered at protocol defined dose. A standard disease-directed therapy will be administered according to Prescribing Information/SmPC. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Number of participants with Dose Limiting Toxicities (DLT)s in Part 1
Tidsram: Up to 28 days
|
Dose-limiting toxicity will be defined as the occurrence of any of the toxicities as per protocol. |
Up to 28 days
|
|
Number of participants with Treatment-emergent Adverse Events (TEAEs)
Tidsram: Up to approximately 2 years
|
Defined as adverse events AE (either reported for the first time or the worsening of a pre-existing event) occurring after the first dose of study drug and up to 60 days after last dose of study drug or until the start of a new disease-directed therapy, whichever occurs first. |
Up to approximately 2 years
|
|
Number of participants with TEAEs leading to dose modification or discontinuation
Tidsram: Up to approximately 2 years
|
Number of participants with TEAEs leading to study drug modifications (interruptions, dose reduction) or discontinuation. |
Up to approximately 2 years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Pharmacokinetics Parameter: Cmax of INCA036978
Tidsram: Up to approximately 2 years
|
Defined as maximum observed plasma concentration of INCA036978. |
Up to approximately 2 years
|
|
Pharmacokinetics Parameter: Tmax of INCA036978
Tidsram: Up to approximately 2 years
|
Defined as the time to reach the maximum plasma concentration of INCA036978. |
Up to approximately 2 years
|
|
Pharmacokinetics Parameter: Cmax,ss of INCA036978
Tidsram: Up to approximately 2 years
|
Defined as the maximum observed plasma concentration at steady state of INCA036978. |
Up to approximately 2 years
|
|
Pharmacokinetics Parameter: Cmin,ss of INCA036978
Tidsram: Up to approximately 2 years
|
Defined as the minimum observed plasma concentration at steady state of INCA036978. |
Up to approximately 2 years
|
|
Pharmacokinetics Parameter: AUC(0-t) of INCA036978
Tidsram: Up to approximately 2 years
|
Defined as the area under the concentration-time curve up to the last measurable concentration of INCA036978. |
Up to approximately 2 years
|
|
Pharmacokinetics Parameter: AUC 0-∞ of INCA036978
Tidsram: Up to approximately 2 years
|
Defined as the area under the concentration-time curve from 0 to infinity of INCA036978. |
Up to approximately 2 years
|
|
Pharmacokinetics Parameter: CL/F of INCA036978
Tidsram: Up to approximately 2 years
|
Defined as the apparent clearance of INCA036978. |
Up to approximately 2 years
|
|
Pharmacokinetics Parameter: Vz/F of INCA036978
Tidsram: Up to approximately 2 years
|
Defined as the apparent volume of distribution of INCA036978. |
Up to approximately 2 years
|
|
Pharmacokinetics Parameter: t1/2 of INCA036978
Tidsram: Up to approximately 2 years
|
Defined as the apparent terminal phase disposition half-life of INCA036978. |
Up to approximately 2 years
|
|
For participants with myelofibrosis (MF): Percentage of participants achieving spleen volume reduction as defined in the protocol
Tidsram: Week 12 and Week 24
|
Defined as percentage of participants with a protocol defined spleen volume reduction. |
Week 12 and Week 24
|
|
For participants with MF and anemia: Anemia Response as defined in the protocol
Tidsram: Up to approximately 2 years
|
For non transfusion-dependent (TD) participants: An Hb increase relative to baseline as defined in the protocol if non-TD at baseline. For TD participants: Achieving transfusion independency (TI) as defined in the protocol. |
Up to approximately 2 years
|
|
For participants with polycythemia vera (PV): Peripheral blood count remission as defined by the protocol.
Tidsram: Up to approximately 2 years
|
Peripheral blood count remission as defined by the protocol. |
Up to approximately 2 years
|
|
For participants with essential thrombocythemia (ET): Peripheral blood count remission as defined by the protocol.
Tidsram: Up to approximately 2 years
|
Peripheral blood count remission as defined by the protocol. |
Up to approximately 2 years
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Incyte Medical Monitor, Incyte Corporation
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Neoplasmer efter plats
- Neoplasmer
- Hematologiska sjukdomar
- Blodkoagulationsstörningar
- Benmärgssjukdomar
- Hemorragiska störningar
- Blodplättssjukdomar
- Benmärgsneoplasmer
- Hematologiska neoplasmer
- Hemiska och lymfsjukdomar
- Trombocytos
- Myeloproliferativa störningar
- Trombocytemi, väsentligt
- Polycytemi Vera
- Primär myelofibros
Andra studie-ID-nummer
- INCA036978-101
- 2026-525217-31-00 (Registeridentifierare: EU CT Number)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .